Aspire Biopharma Holdings (ASBP) Stock Statistics & Valuation Metrics

Aspire Biopharma Holdings has a market cap or net worth of $7.37M. The enterprise value is $5.32M.

Aspire Biopharma Holdings has 3,461,153 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aspire Biopharma Holdings’s return on equity (ROE) is 8.14 and return on invested capital (ROIC) is -48.30%.

The current PE Ratio of Aspire Biopharma Holdings is ―. Aspire Biopharma Holdings’s PEG ratio is 1.59.

In the last 12 months, Aspire Biopharma Holdings had revenue of 0.00 and earned -12.54M in profits. Earnings per share was -0.38.

In the last 12 months, operating cash flow was -1.43M and capital expenditures 0.00, giving a free cash flow of -1.43M billion.

Aspire Biopharma Holdings pays an annual dividend of ―, resulting in a dividend yield of ―

Aspire Biopharma Holdings upcoming earnings date is ―, ―.

Aspire Biopharma Holdings as a current ratio of 0.09, with Debt / Equity ratio of -12.08%

In the past 12 months, Aspire Biopharma Holdings has paid 1.01K in taxes.

Aspire Biopharma Holdings EV to EBITDA ratio is -1.30K, with an EV/FCF ratio of -57.21K.

Aspire Biopharma Holdings has $1.95M in cash and marketable securities with $1.38M in debt, giving a net cash position of $563.49K billion.

Gross margin is 45.54%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Aspire Biopharma Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―